What Is
Soft Tissue
Sarcoma?

ABOUT SOFT TISSUE SARCOMA

Soft tissue sarcoma is a cancer that begins in the soft tissues of the body. This can include the muscles, tendons, fat, blood vessels, or other supporting tissue.

Where soft tissue sarcoma can begin in the body

Soft tissue sarcoma
is considered a rare cancer

EVERY YEAR, APPROXIMATELY

12,000 PEOPLE

ARE DIAGNOSED WITH SOFT TISSUE SARCOMA IN THE U.S.

TYPES OF SOFT TISSUE SARCOMA

There are many different types of soft tissue sarcoma, which are called subtypes.

According to the American Cancer Society, there are more than

Different subtypes of soft tissue sarcoma are usually associated with certain locations in the body and types of tissue.

Common types of soft tissue sarcoma in adults include undifferentiated pleomorphic sarcoma, liposarcoma, and leiomyosarcoma.

SYMPTOMS OF SOFT TISSUE SARCOMA

Soft tissue sarcoma can appear almost anywhere in the body,
and can start as a lump with no other symptoms.

Each subtype is different, so people have different
experiences with symptoms, diagnosis, and treatment.

The first signs of sarcoma can be:

  • A lump that has grown over a period of time

  • Worsening abdominal pain

  • Uncomfortable swelling

  • Limited mobility

  • Pain that feels like a pulled muscle

Getting
Specialized
Care

Because soft tissue sarcoma is rare and there are many subtypes, it can be difficult to diagnose.

Patient advocacy groups recommend consulting a team with experience treating sarcoma,
which can be found at sarcoma centers.

If you’re interested in learning more about sarcoma specialty centers, visit:

Soft tissue sarcoma is treated by a healthcare team that includes doctors with different specialties.

  • Your healthcare team may include a surgical oncologist, a radiation oncologist,
    and an oncology nurse

Your healthcare team may use a range of tests to diagnose your disease and plan treatment that is right for you.

  • Tests may include a biopsy or imaging tests such as a CT scan or MRI. A biopsy is a procedure in which your doctor will remove a tiny piece of tissue and look at it under a microscope. It is the main way doctors diagnose most types of cancer, and the only way to know for sure that it is cancer

You and your healthcare team will work together to develop a treatment plan that is right for you.

x

INDICATION AND IMPORTANT SAFETY INFORMATION

EXPAND

WHO IS LARTRUVO FOR?

LARTRUVO (olaratumab) is a prescription medicine used with a type of chemotherapy called doxorubicin to treat adult patients with soft tissue sarcoma (STS) for whom doxorubicin is appropriate and who cannot be cured with radiation or surgery.

There is an ongoing study to confirm how LARTRUVO works in combination with doxorubicin.

IMPORTANT SAFETY INFORMATION FOR LARTRUVO

What is the most important information I should know about LARTRUVO?

  • Infusion reactions related to injecting LARTRUVO have occurred. Most of these reactions happened during or after the first or second LARTRUVO infusion. Signs and symptoms of infusion reactions include flushing, shortness of breath, severe trouble breathing, or fever/chills. In severe cases, severe low blood pressure, anaphylactic shock (a severe, potentially life-threatening allergic reaction), or cardiac arrest (abrupt loss of heart function) may occur. Tell your doctor if you have any of these symptoms. Your healthcare team will monitor you for these side effects. In the case of a severe infusion reaction, your LARTRUVO treatment will have to be immediately and permanently stopped.

  • LARTRUVO can harm your unborn baby. You should avoid getting pregnant, and use effective birth control while receiving LARTRUVO and for at least 3 months after stopping LARTRUVO.

What are the most common side effects of LARTRUVO?

  • The most common side effects reported in patients treated with LARTRUVO when given in combination with doxorubicin were nausea; tiredness or weakness; pain in the muscles, joints, and bones; sores and swelling of the mouth and digestive tract; hair loss; vomiting; diarrhea; decreased appetite; stomach pain; weakness, numbness, or pain in the hands and feet; and headache.

  • The most common changes to blood tests were low white blood cell count, low platelet count, high blood sugar, increased blood clotting time, low blood potassium level, and low blood phosphate level.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/safety/medwatch or call 1-800-FDA-1088.

What should I tell my doctor before receiving treatment with LARTRUVO?

Before you receive LARTRUVO, tell your doctor if you:

  • Are pregnant or may be pregnant. If you become pregnant during treatment, discuss this with your doctor.

  • Are breastfeeding: your doctor will tell you not to breastfeed during LARTRUVO treatment and for at least 3 months after stopping LARTRUVO.

Tell your doctor about all the medications you are taking, including prescription and over-the-counter medications.

LARTRUVO is available by prescription only.

Please see full Prescribing Information for additional information about LARTRUVO.

OR CON ISI 12JAN2017

WHO IS LARTRUVO FOR?

LARTRUVO (olaratumab) is a prescription medicine used with a type of chemotherapy called doxorubicin to treat adult patients with soft tissue sarcoma (STS) for whom doxorubicin is appropriate and who cannot be cured with radiation or surgery.

There is an ongoing study to confirm how LARTRUVO works in combination with doxorubicin.

IMPORTANT SAFETY INFORMATION FOR LARTRUVO

What is the most important information I should know about LARTRUVO?

  • Infusion reactions related to injecting LARTRUVO have occurred. Most of these reactions happened during or after the first or second LARTRUVO infusion. Signs and symptoms of infusion reactions include flushing, shortness of breath, severe trouble breathing, or fever/chills. In severe cases, severe low blood pressure, anaphylactic shock (a severe, potentially life-threatening allergic reaction), or cardiac arrest (abrupt loss of heart function) may occur. Tell your doctor if you have any of these symptoms. Your healthcare team will monitor you for these side effects. In the case of a severe infusion reaction, your LARTRUVO treatment will have to be immediately and permanently stopped.

  • LARTRUVO can harm your unborn baby. You should avoid getting pregnant, and use effective birth control while receiving LARTRUVO and for at least 3 months after stopping LARTRUVO.

What are the most common side effects of LARTRUVO?

  • The most common side effects reported in patients treated with LARTRUVO when given in combination with doxorubicin were nausea; tiredness or weakness; pain in the muscles, joints, and bones; sores and swelling of the mouth and digestive tract; hair loss; vomiting; diarrhea; decreased appetite; stomach pain; weakness, numbness, or pain in the hands and feet; and headache.

  • The most common changes to blood tests were low white blood cell count, low platelet count, high blood sugar, increased blood clotting time, low blood potassium level, and low blood phosphate level.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/safety/medwatch or call 1-800-FDA-1088.

What should I tell my doctor before receiving treatment with LARTRUVO?

Before you receive LARTRUVO, tell your doctor if you:

  • Are pregnant or may be pregnant. If you become pregnant during treatment, discuss this with your doctor.

  • Are breastfeeding: your doctor will tell you not to breastfeed during LARTRUVO treatment and for at least 3 months after stopping LARTRUVO.

Tell your doctor about all the medications you are taking, including prescription and over-the-counter medications.

LARTRUVO is available by prescription only.

Please see full Prescribing Information for additional information about LARTRUVO.

OR CON ISI 12JAN2017

X

You are now leaving the www.LARTRUVO.com website.

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC, does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC, is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.

  • Continue

  • Cancel

X

For US Healthcare Professionals

The information contained in www.LARTRUVO.com/hcp is technical in nature and intended for healthcare professionals in the United States only.

I'd like information for:

  • Healthcare Professionals

  • Patients and Caregivers